Ultra-long-acting biological therapy for chronic rhinosinusitis with nasal polyps
- PMID: 40037389
- DOI: 10.1016/S0140-6736(25)00367-8
Ultra-long-acting biological therapy for chronic rhinosinusitis with nasal polyps
Conflict of interest statement
P-JW holds a patent and is a shareholder in Chitogel, a company that develops a surgical dressing, and he is also a shareholder and consultant for Fusetec, a company that develops surgical training models; neither of these companies are related to biological agents. P-JW holds a research grant with Sanofi, a company that produces a biological agent; the grant is for investigation into the pathophysiology of chronic rhinosinusitis, and unrelated to biological drugs. P-JW is also a consultant for Neilmed, Medtronic, Stryker, and Integra. P-JW reports travel support from Neilmed and has patents issued with Chitogel and Zeroscar (US 11,590,075B2). SP declares no competing interests.
Comment on
-
Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials.Lancet. 2025 Mar 15;405(10482):911-926. doi: 10.1016/S0140-6736(25)00197-7. Epub 2025 Mar 1. Lancet. 2025. PMID: 40037388 Clinical Trial.
Publication types
LinkOut - more resources
Full Text Sources